ZA201003524B - Injectable meclizine formulations and methods - Google Patents

Injectable meclizine formulations and methods

Info

Publication number
ZA201003524B
ZA201003524B ZA2010/03524A ZA201003524A ZA201003524B ZA 201003524 B ZA201003524 B ZA 201003524B ZA 2010/03524 A ZA2010/03524 A ZA 2010/03524A ZA 201003524 A ZA201003524 A ZA 201003524A ZA 201003524 B ZA201003524 B ZA 201003524B
Authority
ZA
South Africa
Prior art keywords
meclizine
injectable
formulations
methods
meclizine formulations
Prior art date
Application number
ZA2010/03524A
Other languages
English (en)
Inventor
Edwin Curran Murphy
Walker Anderson Long
Original Assignee
Genebiology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genebiology Inc filed Critical Genebiology Inc
Publication of ZA201003524B publication Critical patent/ZA201003524B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2010/03524A 2007-10-31 2010-05-18 Injectable meclizine formulations and methods ZA201003524B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/980,845 US8138192B2 (en) 2007-10-31 2007-10-31 Injectable meclizine formulations and methods
PCT/US2008/081973 WO2009059120A2 (en) 2007-10-31 2008-10-31 Injectable meclizine formulations and methods

Publications (1)

Publication Number Publication Date
ZA201003524B true ZA201003524B (en) 2011-03-30

Family

ID=40583655

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/03524A ZA201003524B (en) 2007-10-31 2010-05-18 Injectable meclizine formulations and methods

Country Status (10)

Country Link
US (2) US8138192B2 (enExample)
EP (1) EP2219606B1 (enExample)
JP (1) JP5462797B2 (enExample)
AU (1) AU2008318536B2 (enExample)
CA (1) CA2704430C (enExample)
ES (1) ES2657937T3 (enExample)
NZ (1) NZ584942A (enExample)
PT (1) PT2219606T (enExample)
WO (1) WO2009059120A2 (enExample)
ZA (1) ZA201003524B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150859A1 (en) * 2010-06-04 2011-12-08 Comprehensive Drug Enterprises Ltd Oral meclizine aqueous formulations with taste flavoring agent
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2019178536A1 (en) * 2018-03-16 2019-09-19 The Regents Of The University Of California Mtor inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60204712A (ja) 1984-03-29 1985-10-16 Ss Pharmaceut Co Ltd 塩酸メクリジンの安定化液状組成物
US4729997A (en) 1985-10-15 1988-03-08 Nastech Pharmaceutical Co., Inc. Novel method of administering meclizine type pharmaceutical agents and novel dosage forms containing same
BE1011251A3 (fr) * 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2002032459A2 (en) 2000-10-17 2002-04-25 Massachusetts Institute Of Technology Method of increasing the efficacy of antibiotics by complexing with cyclodextrins
US20060120967A1 (en) 2004-12-07 2006-06-08 Qpharma, Llc Solution forms of cyclodextrins for nasal or throat delivery of essential oils

Also Published As

Publication number Publication date
EP2219606B1 (en) 2017-12-27
ES2657937T3 (es) 2018-03-07
WO2009059120A3 (en) 2009-08-06
CA2704430C (en) 2016-04-05
CA2704430A1 (en) 2009-05-07
NZ584942A (en) 2012-09-28
US20090111833A1 (en) 2009-04-30
JP2011502169A (ja) 2011-01-20
PT2219606T (pt) 2018-02-02
US8293749B2 (en) 2012-10-23
JP5462797B2 (ja) 2014-04-02
US8138192B2 (en) 2012-03-20
WO2009059120A2 (en) 2009-05-07
EP2219606A4 (en) 2013-03-06
US20120108608A1 (en) 2012-05-03
AU2008318536B2 (en) 2013-09-26
EP2219606A2 (en) 2010-08-25
AU2008318536A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
ZA201001300B (en) Antigen-asjuvant compositions and methods
IL210153A0 (en) Nutrigenomics methods and compositions
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
ZA201203709B (en) Immunogenic compositions and methods
PL2150617T3 (pl) Wzmocniona ekspresja i regiony stabilności
IL210804A (en) Benzylidenehydrazides and their uses
EP2185692A4 (en) HCO32 AND HCO27 AND RELATED EXAMPLES
IL209141A0 (en) Novel substituted pyridin-2-ones and pyridazin-3-ones
SG10201701954QA (en) Anti-cxcr1 compositions and methods
EP2207420A4 (en) ANTIGLIFERING METHOD AND COMPOSITIONS
GB0819530D0 (en) Methods and compositions
GB0808575D0 (en) Compilign and linking
GB0721291D0 (en) Methods and compositions
EP2291377A4 (en) IMIDAZOPYRIMIDINONE AND ITS USES
ZA201103456B (en) Leukolectins and uses thereof
EP2247601A4 (en) THIAZOPYRIMIDINONE AND APPLICATIONS THEREOF
IL213207B (en) Dihydroorphines and their preparation
GB0719526D0 (en) Compositions and methods
ZA201000357B (en) 2-Azetidinemethaneamines and 2-pyrrolidinemethaneamines as Taar-Ligands
IL208824A0 (en) Iminopyridine derivative and use thereof
PT2219606T (pt) Formulações e métodos de meclizina injectável
EP2501771A4 (en) CURABLE POLYAMIDES UNDER MOISTURE ACTION AND METHODS OF USE
EP2274294A4 (en) 5-DIMETHOXY FUMAGILLOL AND ITS DERIVATIVES
GB0811250D0 (en) Methods and compositions
GB0707069D0 (en) Methods and uses